(S (SBAR (IN While) (S (NP (NP (JJ sample) (NNS sizes)) (PP (IN in) (NP (JJ randomized) (JJ clinical) (NNS trials)))) (VP (VBP are) (ADJP (JJ large) (RB enough) (S (VP (TO to) (VP (VB estimate) (NP (DT the) (JJ average) (NN treatment) (NN effect)) (ADVP (RB well))))))))) (, ,) (NP (PRP they)) (VP (VBP are) (ADVP (RB often)) (ADJP (JJ insufficient) (PP (IN for) (NP (NP (NN estimation)) (PP (IN of) (NP (NP (JJ treatment-covariate) (NNS interactions)) (ADJP (JJ critical) (PP (TO to) (S (VP (VBG studying) (NP (JJ data-driven) (NN precision) (NN medicine)))))))))))) (. .))
(S (NP (NP (NNP Observational) (NNS data)) (PP (IN from) (NP (ADJP (JJ real) (NN world)) (NN practice)))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (S (VP (VBG alleviating) (NP (DT this) (NN problem))))))) (. .))
(S (NP (NP (CD One) (JJ common) (NN approach)) (PP (IN in) (NP (NNS trials)))) (VP (VBZ is) (S (VP (TO to) (VP (VP (VB predict) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NN interest)))) (PP (IN with) (NP (NP (JJ separate) (NN regression) (NNS models)) (PP (IN in) (NP (DT each) (NN treatment) (NN arm)))))) (, ,) (CC and) (VP (VB estimate) (NP (DT the) (NN treatment) (NN effect)) (PP (VBN based) (PP (IN on) (NP (NP (DT the) (NN contrast)) (PP (IN of) (NP (DT the) (NNS predictions))))))))))) (. .))
(S (ADVP (RB Unfortunately)) (, ,) (NP (DT this) (JJ simple) (NN approach)) (VP (MD may) (VP (VB induce) (NP (JJ spurious) (JJ treatment-covariate) (NN interaction)) (PP (IN in) (NP (JJ observational) (NNS studies))) (SBAR (WHADVP (WRB when)) (S (NP (DT the) (NN regression) (NN model)) (VP (VBZ is) (VP (VBN misspecified))))))) (. .))
(S (S (VP (VBN Motivated) (PP (IN by) (NP (NP (DT the) (NN need)) (PP (IN of) (S (VP (VBG modeling) (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NNS relapses))) (PP (IN in) (NP (NP (JJ multiple) (NN sclerosis) (NNS patients)) (, ,) (SBAR (WHADVP (WRB where)) (S (NP (NP (DT the) (NN ratio)) (PP (IN of) (NP (NN relapse) (NNS rates)))) (VP (VBZ is) (NP (NP (DT a) (JJ natural) (NN choice)) (PP (IN of) (NP (DT the) (NN treatment) (NN effect))))))))))))))))) (, ,) (NP (PRP we)) (VP (VBP propose) (S (VP (TO to) (VP (VP (VB estimate) (NP (NP (DT the) (JJ conditional) (JJ average) (NN treatment) (NN effect)) (PRN (-LRB- -LRB-) (NP (NNP CATE)) (-RRB- -RRB-))) (PP (IN as) (NP (NP (DT the) (NN ratio)) (PP (IN of) (NP (VBN expected) (JJ potential) (NNS outcomes)))))) (, ,) (CC and) (VP (VB derive) (NP (NP (DT a) (ADJP (RB doubly) (JJ robust)) (NN estimator)) (PP (IN of) (NP (DT this) (NNP CATE)))) (PP (IN in) (NP (NP (DT a) (JJ semiparametric) (NN model)) (PP (IN of) (NP (JJ treatment-covariate) (NNS interactions)))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VBP provide) (NP (NP (DT a) (NN validation) (NN procedure)) (SBAR (S (VP (TO to) (VP (VB check) (NP (NP (DT the) (NN quality)) (PP (IN of) (NP (DT the) (NN estimator)))) (PP (IN on) (NP (DT an) (JJ independent) (NN sample))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP conduct) (NP (NNS simulations)) (S (VP (TO to) (VP (VB demonstrate) (NP (NP (DT the) (JJ finite) (JJ sample) (NN performance)) (PP (IN of) (NP (DT the) (VBN proposed) (NNS methods)))))))) (, ,) (CC and) (VP (VB illustrate) (NP (NP (PRP$ their) (NNS advantages)) (PP (IN on) (NP (JJ real) (NNS data)))) (PP (IN by) (S (VP (VBG examining) (NP (NP (DT the) (NN treatment) (NN effect)) (PP (IN of) (NP (NN dimethyl) (NN fumarate))) (PP (VBN compared) (PP (TO to) (NP (VB teriflunomide)))) (PP (IN in) (NP (JJ multiple) (NN sclerosis) (NNS patients))))))))) (. .))
